In the dynamic of medicinal cannabis business, Australian Little Green Pharma (LGP) has emerged as a formidable force, shaping the industry landscape with its unwavering commitment to providing affordable, pharmaceutical-grade medicinal cannabis to patients worldwide.
Founded in 2016, LGP has rapidly become a global player, addressing over 200 chronic conditions with its range of medicinal cannabis products. Notably, the company’s products are prescribed when traditional treatments fall short, offering therapeutic benefits without undesirable side effects.
With an annual production of approximately 3 tonnes of dried cannabis biomass in Australia and an additional 20 tonnes in Denmark, LGP has strategically positioned itself in diverse markets. The company holds licenses and export access to countries across Europe, the UK, New Zealand, and Brazil.
LGP’s medicinal cannabis brand has gained significant recognition in Europe, the largest medicinal cannabis market outside North America. In 2023, the company strategically targeted new European countries and distribution partners, solidifying its presence with exclusivity agreements in Germany and the UK. LGP supplies key partners in Denmark, Poland, Portugal, and is one of the exclusive suppliers to Italy through government tenders.
Notably, LGP is spearheading a groundbreaking French trial expected to pave the way for the legalization of medicinal cannabis products in 2023. Selected as one of four global suppliers for the French national trial in 2021, LGP has delivered over 52,000 units, establishing itself as the trial’s largest supplier.
LGP’s commitment to ethical clinical research is evident in its independent, science-based approach, reinforcing the therapeutic benefits and safety of medicinal cannabis. In Australia, the company embarked on the world’s largest longitudinal study involving over 3,000 patients, collaborating with esteemed institutions such as Curtin University, the University of Western Australia, and the Harry Perkins Institute.
Beyond medicinal advancements, LGP prioritizes sustainability, contributing significantly to the local economy through its cultivation and manufacturing facility in southwest Western Australia. The company purchases 100% renewable power and employs hydroponic watering systems, showcasing an environmentally responsible ethos.
In a bid to ensure equitable access to medicinal cannabis, LGP operates a compassionate access program, enabling eligible patients facing financial constraints to receive necessary medications. To date, LGP has donated over $1 million worth of medicinal cannabis products through this program, exemplifying a dedication to improving lives globally. (GT)
